Disturbances of events associated with intracellular signaling pathways have been suspected of involvement in the development or progression of affective disorders. Often, heterotrimeric G proteins are located at the beginning of these pathways as modulators of extracellular messages. For this reason, messenger RNA expression of three G protein ␣-subunits and of phosphatidylinositol-3 kinase (PI-3 K) regulatory subunit p85 was examined in granulocytes from patients with bipolar or unipolar affective disorder and compared to healthy controls. Messenger RNA expression of the G protein subunit ␣ q and of p85 was identical in unipolar and bipolar patients and in controls. Furthermore, mRNAs of G protein subunits ␣ s and ␣ i2 were not different in unipolar patients as compared to healthy controls. Alpha s mRNA, however, was markedly increased in bipolar patients. This increase was observed in lithiumtreated (more than 12 months) and in unmedicated patients. Elevated levels of ␣ i2 mRNA in unmedicated bipolar patients did not reach statistical significance, whereas mRNA in bipolar patients receiving lithium was significantly above controls. Finally, long-term medication of unipolar patients with lithium had no influence on ␣ i2 mRNA levels. The data reveal elevated mRNA levels of G␣ s as a robust feature of bipolar affective disorder. Moreover, despite responsiveness of ␣ i2 gene expression to cAMP-related events, no substantial upregulation of ␣ i2 mRNA was observed in bipolar patients. The lack of ␣ i2 mRNA upregulation, hence, could be an additional abnormality in these patients. Even though lithium was able to reinstate this upregulation, there was no feedback downregulation of ␣ s . This strongly supports the notion of major disturbances of the cAMP signaling system in bipolar illness.
Introduction
There is increasing evidence that genetic predisposition is a crucial factor for the development of complex psychiatric illnesses such as affective disorders. 1, 2 Dependent on environmental risk factors, inherited vulnerability may turn into clinically diagnosable disease very early on or may be obscured for a long period of time. Recent findings emphasize the impact of genetic factors on the likelihood of suffering from major depression after prolonged exposure to severe stress events. 3 A variety of attempts to identify these factors have been made. Increased attention has been dedicated to intracellular signaling events and to processes mediating transduction of environmental changes into the interior of the cell. 4, 5 Located at the crosspoint of Correspondence: Dr PJ Gebicke-Haerter, Dept of Psychiatry, University of Freiburg, Hauptstraße 8, D-79104 Freiburg i Br, Germany. E-mail: PeterFGebicke-Haerter®psyallg.ukl.uni-freiburg.de Abbreviations: GAPDH, glycerolaldehydephosphate dehydrogenase; GTC, guanidinium isothiocyanate; IP, inositol phospholipid; PBS, phosphate-buffered saline; PI-3K, phosphatidyl inositol-3 kinase; RT-PCR, reverse transcriptase-polymerase chain reaction; s12, ribosomal protein s12. Received 25 November 1997; revised and accepted 10 February 1998 outside and inside of the cell, heterotrimeric G proteins are crucial molecular switches relaying and amplifying environmental signals. An increasing body of evidence from clinical and experimental studies suggests involvement of abnormal function and/or expression of these proteins in the pathophysiology of bipolar affective disorders. [6] [7] [8] Typically, receptor-activated G proteins dissociate into ␣ and ␤␥ subunits which can trigger cascades of intracellular responses. Alpha subunits are a family of proteins with molecular weights between 39 and 52 kDa sharing 45-80% amino acid homology. Based on their amino acid sequences, they have been subgrouped into four classes: ␣ s , ␣ i , ␣ q , and ␣ 12 . Until now, 20 different ␣ subunits, five ␤ and 12␥ subunits have been described. [9] [10] [11] There is no indication of mutations or other defects in the gene of the G protein subunit ␣ s in affective illness. 12 However, abnormalities in the expression of G protein ␣ subunits have been found in postmortem brains and peripheral blood cells from patients with bipolar affective disorder. [13] [14] [15] Alpha s immunoreactivity and forskolin-activated adenylyl cyclase activity was elevated in brains of these patients. 13, 14 Determinations of ␣ s mRNA, however, revealed no differences compared to controls. 16 In mononuclear leukocytes obtained from bipolar patients, ␣ s and ␣ i protein levels were increased (160% and 115%, respectively) and no changes were seen in major depressives compared to controls. 15 Furthermore, GppNHp binding to G proteins in mononuclear leukocyte membranes upon ␤-adrenergic or muscarinic stimulation was greater in manic than in euthymic patients. 17 High levels of G␣ s were also found in platelets but not in lymphocytes of bipolar patients. 18 The data support the notion that hyperfunctional stimulatory and inhibitory G proteins are involved in the pathology of affective disorders and suggest that such irregularities may occur and be detectable in peripheral blood cells.
Our previous studies revealed differential release of intracellular calcium and inositol phosphates in neutrophils from patients with major depression in comparison to lithium-treated patients, which led us to assume that components of second messenger pathways might be abnormal in the disease. [19] [20] [21] Therefore, the present study was aimed at investigating the expression of G protein mRNA levels in neutrophils obtained from patients with affective disorder. To this end, quantitation of mRNA levels of ␣ s , ␣ i2 , and ␣ q as well as mRNA of p85 regulatory subunit of PI-3 kinase, 22 which is distantly related to G protein function, was carried out by an elaborate, competitive RT-PCR method. 23 Patients without medication and patients with long-term lithium treatment were included to assess the influence of this important prophylactic and therapeutic agent. 24 The results clearly reveal specifically elevated and lithium-independent mRNA levels of ␣ s and lithium-mediated upregulation of ␣ i2 mRNA in bipolar patients.
Materials and methods

Subjects
For mRNA determinations of ␣ s , blood was obtained from 11 bipolar and 16 unipolar patients who met DSM-III-R criteria for major depression, and from 14 controls. For mRNA determinations of ␣ i2 , blood was obtained from 16 bipolar and 22 unipolar patients who met DSM-III-R criteria for major depression, and from 23 controls. Unipolar and bipolar patients receiving lithium were on this medication for at least one year and were treated with no additional drugs. Lithium concentrations were routinely determined in our laboratory. Blood levels of all patients were within the therapeutic range of 0.4-0.8 mM L −1 . For mRNA determinations of ␣ q , blood was obtained from 12 bipolar patients, from 18 unipolar patients, and from 16 controls. p85 mRNAs were determined from blood samples of 12 bipolar patients, 14 unipolar patients, and 13 controls. The majority of patients and control individuals investigated in this study were identical in each of the four marker groups. Further details are listed in Table 1 . After complete description of the study to the subjects, written informed consent was obtained. In all four groups (a-d) the majority of patients and controls investigated were identical; different figures result from availability and quantities of single RNA preparations.
Isolation of neutrophils
Neutrophils were isolated from heparinized blood after sedimentation through dextran 400 (0.6% wt/vol; Pharmacia, Freiburg, Germany), centrifugation through Ficoll-Hypaque (Pharmacia) and subsequent hypotonic lysis of erythrocytes.
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RNA extraction Neutrophils isolated from 20 ml blood were resuspended in 1 ml PBS and lysed in 2.5 ml GTC. Lysates were vigorously vortexed, triturated approximately 10 times through a 22-gauge needle and stored at −20°C until extraction. RNA was extracted according to Chomczynski and Sacchi. 26 One hundred millilitres of 2 M Na-acetate, 500 ml RNA phenol and 100 ml chloroform/isoamylethanol (49:1 vol/vol) were added to 0.5 ml of lysate, mixed and incubated on ice for 20 min. After centrifugation at 10 000 × g, the upper phase was transferred in a new vial and precipitated by adding 1 vol isopropanol. The pellet was washed in 70% ethanol and air-dried. RNA was then dissolved in 10-20 l H 2 O.
Quantitative RT-PCR (a) RT-PCR
Typically, 1 g RNA was reverse transcribed, using MuMLV-reverse transcriptase (Gibco-BRL, Eggenstein, Germany) and random hexamers. PCR was then carried out adding Taq polymerase (Pharmacia, Freiburg, Germany) and a pair of primers specific for respective cDNA species. Table 2 shows primer sequences, temperature conditions, number of cycles and sizes of resulting PCR products. PCR products were cloned directly into pCR™II vector (Invitrogen, San Diego, CA, USA) and transformed into One Shot INVaFЈ bacteria. After selection of insertbearing clones, inserts were sequenced to verify identity with published sequences. 22, [27] [28] [29] (b) Construction of internal standards Insert-bearing plasmids were treated with suitable restriction enzymes to excise appropriate pieces of cDNA. Restriction enzymes used for respective cDNA inserts and resulting sizes of shortened standards are listed in Table 3 . After ligation, the plasmid-containing standard (shortened) cDNA fragment was again transformed into INVaFЈ bacteria and sequenced. These standards were excised and added in various quantities, after reverse transcription of total RNA, to the Figure 1a , lower band) were multiplied by the ratio of the number of base pairs between upper and lower bands to compensate for differences of ethidium bromide incorporation. Then, by an approximation procedure, intensities of internal standards were calculated where this ratio was 1.0. At (a) Electrophoretic separation of PCR products obtained from neutrophil RNA after addition of increasing amounts (from left to right) of shortened cDNA standard (lower band, 390 bp) and using primers for ␣ i2 (see Table 1 ). Left and right lanes = 100 bp markers (MW). (b) Precise determination of unknown cDNA quantities by reading the quantity of the known standard (x-axis) at the point of equilibrium (0 on the y-axis), where both standard and unknown cDNA are equal.
this ratio, the known concentration of internal standard
) and concentration of cDNA are equal (Figure 1b) .
To assess RNA quality and efficacy of reverse transcription, two external standardizations were introduced. From all RT-mixtures included in the study, three 1-l aliquots were also PCR-amplified using s12 30 or GAPDH 31 primers. The means of the best three values were set to 100%. These were then divided by the means of the three intensity values of each other sample, resulting in correction factors (typically in the range of 10%). Samples with deviations of more than 25% from the 100% values were excluded from the study (insufficient RNA quality). The concentrations determined above by the internal standards were finally multiplied by the respective correction factors, very closely reflecting the variable qualities of the different RNA preparations. All PCRs with primers specific for the four cDNAs tested were repeated three times with each individual sample.
Statistical methods
Testing of each group with controls was performed by Student's t-test at a significance level of ␣ = 0.01 with Bonferroni correction due to multiple testing. Intraand inter-assay coefficients of variation were 8.7% and 13.6%, respectively.
Results
Elevated levels of G␣ s mRNA in patients with bipolar but not with unipolar affective illness
Alpha s mRNA concentrations determined from neutrophils obtained from patients free of any medication and diagnosed bipolar I (bp) were markedly increased (Figure 2a,b ; open circles; P Ͻ 0.001). This elevated level was unchanged in a comparable group of patients receiving lithium for more than 12 months and free of any additional medication for at least 2 weeks ( Figure  2 , filled circles). In contrast, both unmedicated and lithium-treated unipolar patients (up), showed no increased ␣ s mRNA levels above controls (Figure 2a ,b, open circles, and Table 4 ). The results were highly significant upon normalization to both s12 or GAPDH standards.
Figures 2-5 are given to show distributions of single results, whereas Table 4 is a summary of all datawithout subgroups-showing means ± s.e.m.
Ga i2 mRNA levels in patients with bipolar but not with unipolar affective illness are increased by lithium treatment
Neutrophils obtained from unmedicated patients and diagnosed bipolar I (bp) showed enhanced ␣ i2 mRNA concentrations, which did not reach statistically significant levels (Figure 3b, open circles) . In patients treated with lithium for more than 12 months and free of any additional medication for at least 2 weeks, these mRNA concentrations markedly differed from controls (P Ͻ 0.01). Alpha i2 mRNA was approximately 100% higher than in lithium-treated unipolar patients (P Ͻ Table 1a . up = unipolar; bp = bipolar; co = controls. 0.01), whose ␣ i2 mRNAs were in the range of healthy controls (Figure 3 a,b) . As with ␣ s mRNA, ␣ i2 mRNA was also unaffected in unipolar patients by long-term lithium intake ( Figure 3) . The results were highly significant upon normalization to both s12 or GAPDH standards. In both uni-and bipolar patients, there was no correlation between the plasma levels of lithium and ␣ i2 mRNA concentrations.
Lack of effects on G␣ q , or on p85 mRNA expression
In contrast to ␣ s and ␣ i2 mRNAs, ␣ q mRNA concentrations in neutrophils from bipolar patients were indistinguishable from unipolar patients or healthy individuals ( Figure 4 , open circles). There was also no measurable effect of lithium on this mRNA expression whatsoever ( Figure 4 , filled circles). Messenger RNA expression of p85, the regulatory subunit of PI-3 kinase, was not significantly different from controls in all groups investigated ( Figure 5 and Table 4 ). Furthermore, in long-term lithium-treated uni-or bipolar patients, this mRNA expression was in the same range as in unmedicated, healthy controls.
Discussion
The present data support the notion that disturbances of receptor-coupled G proteins are associated with affective disorder. The method of quantitative, competitive RT-PCR using cDNA constructs specific for each cDNA as internal standards (Figure 1 ) is presently the most reliable means to determine mRNA concentrations from low amounts of material. Additionally, absolute values computed by this procedure were normalized to s12 and GAPDH 'housekeeping' standards to assess 'quality' of RNA preparation and efficiency of reverse transcription. The approach allows for the collection of significant data within a short time with relatively low n-numbers. A possible drawback inherent to this and a number of comparable studies is the cellular source originating from the periphery (for detailed discussion see Ref 18) . There are, however, reports showing elevated ␣ s protein in occipital and frontal cortex and increased forskolin-stimulated cAMP formation in post-mortem brains of bipolar patients. 13, 14 Later on, high ␣ s levels were measured also in leukocytes and, very recently, in platelets from bipolar depressed patients, 15, 18, 32 suggesting parallelism of events in brain and periphery. Our choice of neutrophils for the present investigation was due to our greater experimental experience with these cells. Although we cannot provide protein data for this cell type, the mRNA data are in keeping with the protein data reported from the other blood cell types and from human brain. Since we have not investigated mRNA expression in postmortem brains from bipolar patients, we are unable to explain the recent negative findings of correlation by others. Table 1b . up = unipolar; bp = bipolar; co = controls. Upregulation of ␣ s mRNA in human neutrophils appears to be specific for bipolar illness, since patients with unipolar diagnoses clearly fall in the range of controls. These elevated levels of ␣ s mRNA largely corroborate the above mentioned findings 15, 18, 32 and suggest no substantial regulation on the translational level. The hypothesis of ␣ s as a trait marker for bipolar affective disorder is further substantiated by our data showing increased expression of ␣ s mRNA in neutrophils of remitted patients under long-term lithium treatment. As shown recently, lithium also had no effect on ␣ s protein concentration in platelets from bipolar Table 1d . up = unipolar; bp = bipolar; co = controls.
patients. 18 Moreover, in agreement with data obtained from mononuclear leukocytes for ␣ s -and ␣ i -protein, 33 preliminary data from our laboratory indicate no influence of antidepressants on ␣ s mRNA expression.
Elevated levels of ␣ s mRNA and protein in bipolar patients, consequently encompass sustained upregulation of ␣ s gene transcription and increased cAMP concentrations in the disease. One reason for this may be that feedback down-regulation of ␣ s mRNA is counteracted by aberrant events at the promoter site of the gene. Although our data suggest inherited vulnerability, linkage studies have excluded an association of the ␣ s gene with the disease. 34 Moreover, mutations in this gene in vulnerable or diseased patients are unlikely. 12 The promoter region of the ␣ s gene has been sequenced and characterized. 35 Its GC-content is extremely high (85%). Several GC-boxes but no typical TATA-or CAAT-boxes have been found identifying it as a typical 'housekeeping' gene. Furthermore, there is a domain homologous to the human c-Ki-ras2 protooncogene, which may suggest cooperativity of this ␣-subunit with small G proteins in the kinase cascade signaling pathway. Although there are presently no cues as to how upregulation of the ␣ s gene in bipolar disorder is maintained, defects in some transcription factor gene involved in the regulation of the ␣ s gene should be taken into consideration. This would give rise to the hypothesis that the interplay of a greater number of gene products leads to the illness but only a few factors regulating these genes are defective.
Surprisingly, ␣ i2 mRNA was not significantly elevated in unmedicated, bipolar patients, which also correlates well with previous findings by others on the protein level. 15 Like the promoter of the ␣ s gene, the promoter of the ␣ i2 gene shows features typical of 'housekeeping' genes. Additionally, there is a domain homologous to another proto-oncogene, the c-Ha-ras proto-oncogene. 36 Although there is no cAMP-responsive element (CRE) in the ␣ i2 gene promoter, increased ␣ s protein concentrations-in healthy conditionsinduce a rise of ␣ i2 mRNA transcription 37 and rapid feedback down-regulation of ␣ s protein by upregulated ␣ i2 protein, which resets the system back to steady state. [38] [39] [40] Instead, a CCAAT-box in the promoter of the ␣ i2 gene has been identified and suggested to be responsible for cAMP-dependent regulation of the gene. 37 Hence, CCAAT-binding nuclear factors may be regulated by cAMP through CREs in their promoter regions, such as CEB/P 41 ( Figure 6 ). Provided the ␣ i2 gene is normal in bipolar patients, abnormal functions of components of the cAMP signaling cascade have also to be taken into consideration, including adenylyl cyclase and protein kinase A. 42 The lack of ␣ i2 upregulation in bipolar patients, hence, may be an additional key event in the course of the disease. Together with upregulated ␣ s , the data reveal disturbances in the cross-talk between second messenger pathways in bipolar illness. Lithium treatment only affects the level of ␣ i2 mRNA in neutrophils of bipolar but not of unipolar patients. The reasons for this specificity are presently unclear. Conceivably, lithium medication remedies the lack of ␣ i2 response to ␣ s -upregulation in bipolar patients. In agreement with our mRNA data, ␣ i2 protein has also been found to be enhanced in lithium-treated bipolar patients by other investigators. 18 Although a number of effects of lithium on cellular proteins have been reported, the molecular mechanisms responsible for this effect of lithium warrant further investigations. Apparently, these molecular mechanisms only become activated when ␣ s levels are high, which means that elevated cAMP concentrations unlock lithium-triggered events targeted at the ␣ i2 promoter. In other words, in unipolar patients, where ␣ s levels are low, no ␣ i2 mRNA increases were observed under lithium medication.
Evidently, ␣ s mRNA levels are unimpressed by lithium-mediated increases of ␣ i2 . Enhanced concentrations of ␣ i2 protein may, nevertheless, exert a dampening effect on the cAMP signaling pathway. Additionally, substantial effects of lithium on G protein function have been reported, on G␣ s and G␣ i , in particular. [43] [44] [45] These findings suggest that lithium also affects posttranslational events. Other effects of lithium involve its inhibition of polyphospho-inositol monophosphatase (IMPase), 46 which is a key element in the phosphoinositol (PI)-pathway. This gave rise to the hypothesis that overactivation of the IP-pathway in affective disorders is attenuated by lithium, 47 although there are reports at variance with this hypothesis. 24 Apparently, abnormal ␣ s and ␣ i2 mRNA expression are two major features in bipolar illness, since mRNAs encoding other signaling components were unchanged. The level of ␣ q mRNA, the translation product of which stimulates phosphoinositol bisphosphate (PIP2) hydrolysis by phospholipase C and subsequent inositol trisphosphate (IP3) formation, was not changed. Similarly, mRNA of p85 subunit of PI-3 kinase was unaffected. PI-3 kinase is a key enzyme in the ras/raf/MAP kinase pathway, but it also cross-links to the IP second messenger pathway. 48 Investigations on its mRNA expression were included in the study, because the enzyme is located at the beginning of intracellular signaling events.
In summary, this study provides first evidence that mRNAs of G protein subunits ␣ s and ␣ i2 are differentially affected in peripheral cells of bipolar but not of unipolar patients. Upregulated ␣ s mRNA is unresponsive to lithium therapy, wheras low concentrations of ␣ i2 mRNA in unmedicated bipolar patients can be raised by lithium. Abnormal regulation of both genes may be subject to genetic defects of regulatory factors. The results lend support to the concept that abnormalities in G protein expression constitute an important part in the pathophysiology of bipolar affective disorders.
